Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Jul;70(7):4598–4606. doi: 10.1128/jvi.70.7.4598-4606.1996

Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

A McKnight 1, C Shotton 1, J Cordell 1, I Jones 1, G Simmons 1, P R Clapham 1
PMCID: PMC190396  PMID: 8676486

Abstract

Eleven rat monoclonal antibodies (MAbs) that recognize the SU glycoprotein of human immunodeficiency virus type 2 (HIV-2) ROD were produced and characterized. Binding sites for eight of these MAbs were mapped to epitopes within the Cl, V1/V2, C2, and V3 envelope regions. The three other MAbs defined at least two conformation-dependent, strain-specific epitopes outside Vl/V2, V3, and the CD4-binding site. The MAbs were used to probe the tertiary structure of oligomeric envelope glycoprotein expressed on the surfaces of infected cells. Epitopes at the apices of V2 and V3 were exposed on the native molecule, whereas other epitopes on V1/V2, Cl, and C2 were hidden. The MAbs defined three neutralization targets on exposed domains: two linear epitopes in the V2 and the V3 loops and one conformational epitope outside V1, V2, and V3.

Full Text

The Full Text of this article is available as a PDF (392.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babas T., Benichou S., Guetard D., Montagnier L., Bahraoui E. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2. Mol Immunol. 1994 Apr;31(5):361–369. doi: 10.1016/0161-5890(94)90114-7. [DOI] [PubMed] [Google Scholar]
  2. Babu P. G., Saraswathi N. K., Devapriya F., John T. J. The detection of HIV-2 infection in southern India. Indian J Med Res. 1993 Mar;97:49–52. [PubMed] [Google Scholar]
  3. Benichou S., Legrand R., Nakagawa N., Faure T., Traincard F., Vogt G., Dormont D., Tiollais P., Kieny M. P., Madaule P. Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1165–1170. doi: 10.1089/aid.1992.8.1165. [DOI] [PubMed] [Google Scholar]
  4. Björling E., Broliden K., Bernardi D., Utter G., Thorstensson R., Chiodi F., Norrby E. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6082–6086. doi: 10.1073/pnas.88.14.6082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Björling E., Chiodi F., Utter G., Norrby E. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2. J Immunol. 1994 Feb 15;152(4):1952–1959. [PubMed] [Google Scholar]
  6. Bou-Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P., Norcross M. A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol. 1994 Sep;68(9):6006–6013. doi: 10.1128/jvi.68.9.6006-6013.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Breuer J., Douglas N. W., Goldman N., Daniels R. S. Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HIV-2a subtype. J Gen Virol. 1995 Feb;76(Pt 2):333–345. doi: 10.1099/0022-1317-76-2-333. [DOI] [PubMed] [Google Scholar]
  8. Broliden P. A., Mäkitalo B., Akerblom L., Rosen J., Broliden K., Utter G., Jondal M., Norrby E., Wahren B. Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies. Immunology. 1991 Aug;73(4):371–376. [PMC free article] [PubMed] [Google Scholar]
  9. Broliden P. A., von Gegerfelt A., Clapham P., Rosen J., Fenyö E. M., Wahren B., Broliden K. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):461–465. doi: 10.1073/pnas.89.2.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Clapham P. R., Blanc D., Weiss R. A. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology. 1991 Apr;181(2):703–715. doi: 10.1016/0042-6822(91)90904-P. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clapham P. R., McKnight A., Weiss R. A. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol. 1992 Jun;66(6):3531–3537. doi: 10.1128/jvi.66.6.3531-3537.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Clapham P. R., Weiss R. A., Dalgleish A. G., Exley M., Whitby D., Hogg N. Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology. 1987 May;158(1):44–51. doi: 10.1016/0042-6822(87)90236-4. [DOI] [PubMed] [Google Scholar]
  13. Clavel F., Guyader M., Guétard D., Sallé M., Montagnier L., Alizon M. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature. 1986 Dec 18;324(6098):691–695. doi: 10.1038/324691a0. [DOI] [PubMed] [Google Scholar]
  14. Clavel F., Mansinho K., Chamaret S., Guetard D., Favier V., Nina J., Santos-Ferreira M. O., Champalimaud J. L., Montagnier L. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med. 1987 May 7;316(19):1180–1185. doi: 10.1056/NEJM198705073161903. [DOI] [PubMed] [Google Scholar]
  15. Cordell J., Moore J. P., Dean C. J., Klasse P. J., Weiss R. A., McKeating J. A. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology. 1991 Nov;185(1):72–79. doi: 10.1016/0042-6822(91)90755-z. [DOI] [PubMed] [Google Scholar]
  16. Davis D., Stephens D. M., Carne C. A., Lachmann P. J. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope. J Gen Virol. 1993 Dec;74(Pt 12):2609–2617. doi: 10.1099/0022-1317-74-12-2609. [DOI] [PubMed] [Google Scholar]
  17. Dean C. J., Gyure L. A., Hall J. G., Styles J. M. Production of IgA-secreting rat X rat hybridomas. Methods Enzymol. 1986;121:52–59. doi: 10.1016/0076-6879(86)21008-3. [DOI] [PubMed] [Google Scholar]
  18. Denis F., Barin F., Gershy-Damet G., Rey J. L., Lhuillier M., Mounier M., Leonard G., Sangare A., Goudeau A., M'Boup S. Prevalence of human T-lymphotropic retroviruses type III (HIV) and type IV in Ivory Coast. Lancet. 1987 Feb 21;1(8530):408–411. doi: 10.1016/s0140-6736(87)90118-8. [DOI] [PubMed] [Google Scholar]
  19. Franchini G., Fargnoli K. A., Giombini F., Jagodzinski L., De Rossi A., Bosch M., Biberfeld G., Fenyo E. M., Albert J., Gallo R. C. Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2433–2437. doi: 10.1073/pnas.86.7.2433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Fung M. S., Sun C. R., Gordon W. L., Liou R. S., Chang T. W., Sun W. N., Daar E. S., Ho D. D. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol. 1992 Feb;66(2):848–856. doi: 10.1128/jvi.66.2.848-856.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Goudsmit J., Debouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J., Jr, Gajdusek D. C. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478–4482. doi: 10.1073/pnas.85.12.4478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Grez M., Dietrich U., Balfe P., von Briesen H., Maniar J. K., Mahambre G., Delwart E. L., Mullins J. I., Rübsamen-Waigmann H. Genetic analysis of human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. J Virol. 1994 Apr;68(4):2161–2168. doi: 10.1128/jvi.68.4.2161-2168.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Guyader M., Emerman M., Sonigo P., Clavel F., Montagnier L., Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987 Apr 16;326(6114):662–669. doi: 10.1038/326662a0. [DOI] [PubMed] [Google Scholar]
  24. Haigwood N. L., Shuster J. R., Moore G. K., Lee H., Skiles P. V., Higgins K. W., Barr P. J., George-Nascimento C., Steimer K. S. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses. 1990 Jul;6(7):855–869. doi: 10.1089/aid.1990.6.855. [DOI] [PubMed] [Google Scholar]
  25. Ho D. D., Fung M. S., Cao Y. Z., Li X. L., Sun C., Chang T. W., Sun N. C. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949–8952. doi: 10.1073/pnas.88.20.8949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ho D. D., McKeating J. A., Li X. L., Moudgil T., Daar E. S., Sun N. C., Robinson J. E. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol. 1991 Jan;65(1):489–493. doi: 10.1128/jvi.65.1.489-493.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hoxie J. A. Hypothetical assignment of intrachain disulfide bonds for HIV-2 and SIV envelope glycoproteins. AIDS Res Hum Retroviruses. 1991 Jun;7(6):495–499. doi: 10.1089/aid.1991.7.495. [DOI] [PubMed] [Google Scholar]
  28. Javaherian K., Langlois A. J., LaRosa G. J., Profy A. T., Bolognesi D. P., Herlihy W. C., Putney S. D., Matthews T. J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 1990 Dec 14;250(4987):1590–1593. doi: 10.1126/science.1703322. [DOI] [PubMed] [Google Scholar]
  29. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768–6772. doi: 10.1073/pnas.86.17.6768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Javaherian K., Langlois A. J., Montefiori D. C., Kent K. A., Ryan K. A., Wyman P. D., Stott J., Bolognesi D. P., Murphey-Corb M., Larosa G. J. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. J Virol. 1994 Apr;68(4):2624–2631. doi: 10.1128/jvi.68.4.2624-2631.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Javaherian K., Langlois A. J., Schmidt S., Kaufmann M., Cates N., Langedijk J. P., Meloen R. H., Desrosiers R. C., Burns D. P., Bolognesi D. P. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418–1422. doi: 10.1073/pnas.89.4.1418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kang C. Y., Hariharan K., Posner M. R., Nara P. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. J Immunol. 1993 Jul 1;151(1):449–457. [PubMed] [Google Scholar]
  33. Kang C. Y., Nara P., Chamat S., Caralli V., Ryskamp T., Haigwood N., Newman R., Köhler H. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6171–6175. doi: 10.1073/pnas.88.14.6171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kanki P. J., Barin F., M'Boup S., Allan J. S., Romet-Lemonne J. L., Marlink R., McLane M. F., Lee T. H., Arbeille B., Denis F. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science. 1986 Apr 11;232(4747):238–243. doi: 10.1126/science.3006256. [DOI] [PubMed] [Google Scholar]
  35. Kent K. A., Gritz L., Stallard G., Cranage M. P., Collignon C., Thiriart C., Corcoran T., Silvera P., Stott E. J. Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS. 1991 Jul;5(7):829–836. doi: 10.1097/00002030-199107000-00006. [DOI] [PubMed] [Google Scholar]
  36. Kent K. A., Rud E., Corcoran T., Powell C., Thiriart C., Collignon C., Stott E. J. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1147–1151. doi: 10.1089/aid.1992.8.1147. [DOI] [PubMed] [Google Scholar]
  37. Kodama T., Burns D. P., Silva D. P., Veronese F. D., Desrosiers R. C. Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus. J Virol. 1991 Apr;65(4):2010–2018. doi: 10.1128/jvi.65.4.2010-2018.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kulkarni S., Thakar M., Rodrigues J., Banerjee K. HIV-2 antibodies in serum samples from Maharashtra state. Indian J Med Res. 1992 Sep;95:213–215. [PubMed] [Google Scholar]
  39. Lasky L. A., Nakamura G., Smith D. H., Fennie C., Shimasaki C., Patzer E., Berman P., Gregory T., Capon D. J. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell. 1987 Sep 11;50(6):975–985. doi: 10.1016/0092-8674(87)90524-1. [DOI] [PubMed] [Google Scholar]
  40. Luo L., Li Y., Cannon P. M., Kim S., Kang C. Y. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10527–10531. doi: 10.1073/pnas.89.21.10527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Matsushita S., Matsumi S., Yoshimura K., Morikita T., Murakami T., Takatsuki K. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120. J Virol. 1995 Jun;69(6):3333–3340. doi: 10.1128/jvi.69.6.3333-3340.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Hoshino H., Javaherian K., Takatsuki K., Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol. 1988 Jun;62(6):2107–2114. doi: 10.1128/jvi.62.6.2107-2114.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Matthews T. J., Langlois A. J., Robey W. G., Chang N. T., Gallo R. C., Fischinger P. J., Bolognesi D. P. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9709–9713. doi: 10.1073/pnas.83.24.9709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. McKeating J. A., Cordell J., Dean C. J., Balfe P. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology. 1992 Dec;191(2):732–742. doi: 10.1016/0042-6822(92)90249-o. [DOI] [PubMed] [Google Scholar]
  45. McKeating J. A., Shotton C., Cordell J., Graham S., Balfe P., Sullivan N., Charles M., Page M., Bolmstedt A., Olofsson S. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol. 1993 Aug;67(8):4932–4944. doi: 10.1128/jvi.67.8.4932-4944.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. McKnight A., Clapham P. R., Weiss R. A. HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages. Virology. 1994 May 15;201(1):8–18. doi: 10.1006/viro.1994.1260. [DOI] [PubMed] [Google Scholar]
  47. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F., 3rd, Burton D. R., Ho D. D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol. 1995 Jan;69(1):101–109. doi: 10.1128/jvi.69.1.101-109.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Moore J. P., Sattentau Q. J., Wyatt R., Sodroski J. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol. 1994 Jan;68(1):469–484. doi: 10.1128/jvi.68.1.469-484.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Moore J. P., Sattentau Q. J., Yoshiyama H., Thali M., Charles M., Sullivan N., Poon S. W., Fung M. S., Traincard F., Pinkus M. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J Virol. 1993 Oct;67(10):6136–6151. doi: 10.1128/jvi.67.10.6136-6151.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Moore J. P., Trkola A., Korber B., Boots L. J., Kessler J. A., 2nd, McCutchan F. E., Mascola J., Ho D. D., Robinson J., Conley A. J. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol. 1995 Jan;69(1):122–130. doi: 10.1128/jvi.69.1.122-130.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Morikawa Y., Moore J. P., Fenouillet E., Jones I. M. Complementation of human immunodeficiency virus glycoprotein mutations in trans. J Gen Virol. 1992 Aug;73(Pt 8):1907–1913. doi: 10.1099/0022-1317-73-8-1907. [DOI] [PubMed] [Google Scholar]
  52. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993 Nov;67(11):6642–6647. doi: 10.1128/jvi.67.11.6642-6647.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Nandi J., Kamat H., Bhavalkar V., Banerjee K. Detection of human immunodeficiency virus antibody among homosexual men from Bombay. Sex Transm Dis. 1994 Jul-Aug;21(4):235–236. doi: 10.1097/00007435-199407000-00011. [DOI] [PubMed] [Google Scholar]
  54. Norrby E., Putkonen P., Böttiger B., Utter G., Biberfeld G. Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1. AIDS Res Hum Retroviruses. 1991 Mar;7(3):279–285. doi: 10.1089/aid.1991.7.279. [DOI] [PubMed] [Google Scholar]
  55. Palker T. J., Clark M. E., Langlois A. J., Matthews T. J., Weinhold K. J., Randall R. R., Bolognesi D. P., Haynes B. F. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932–1936. doi: 10.1073/pnas.85.6.1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Pfützner A., Dietrich U., von Eichel U., von Briesen H., Brede H. D., Maniar J. K., Rübsamen-Waigmann H. HIV-1 and HIV-2 infections in a high-risk population in Bombay, India: evidence for the spread of HIV-2 and presence of a divergent HIV-1 subtype. J Acquir Immune Defic Syndr. 1992 Oct;5(10):972–977. [PubMed] [Google Scholar]
  57. Pichard E., Guindo A., Grossetete G., Fofana Y., Maiga Y. I., Koumare B., Traore S., Maiga M., Brun-Vezinet F., Rosenheim M. L'infection par le virus de l'immunodéficience humaine (VIH) au Mali. Med Trop (Mars) 1988 Oct-Dec;48(4):345–349. [PubMed] [Google Scholar]
  58. Robert-Guroff M., Aldrich K., Muldoon R., Stern T. L., Bansal G. P., Matthews T. J., Markham P. D., Gallo R. C., Franchini G. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J Virol. 1992 Jun;66(6):3602–3608. doi: 10.1128/jvi.66.6.3602-3608.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Rübsamen-Waigmann H., Briesen H. V., Maniar J. K., Rao P. K., Scholz C., Pfützner A. Spread of HIV-2 in India. Lancet. 1991 Mar 2;337(8740):550–551. doi: 10.1016/0140-6736(91)91333-p. [DOI] [PubMed] [Google Scholar]
  60. Rübsamen-Waigmann H., Maniar J., Gerte S., Brede H. D., Dietrich U., Mahambre G., Pfützner A. High proportion of HIV-2 and HIV-1/2 double-reactive sera in two Indian states, Maharashtra and Goa: first appearance of an HIV-2 epidemic along with an HIV-1 epidemic outside of Africa. Zentralbl Bakteriol. 1994 Jan;280(3):398–402. doi: 10.1016/s0934-8840(11)80603-1. [DOI] [PubMed] [Google Scholar]
  61. Schulz T. F., Whitby D., Hoad J. G., Corrah T., Whittle H., Weiss R. A. Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia. J Virol. 1990 Oct;64(10):5177–5182. doi: 10.1128/jvi.64.10.5177-5182.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Schutten M., McKnight A., Huisman R. C., Thali M., McKeating J. A., Sodroski J., Goudsmit J., Osterhaus A. D. Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. AIDS. 1993 Jul;7(7):919–923. doi: 10.1097/00002030-199307000-00003. [DOI] [PubMed] [Google Scholar]
  63. Shotton C., Arnold C., Sattentau Q., Sodroski J., McKeating J. A. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol. 1995 Jan;69(1):222–230. doi: 10.1128/jvi.69.1.222-230.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Smallman-Raynor M., Cliff A. The spread of human immunodeficiency virus type 2 into Europe: a geographical analysis. Int J Epidemiol. 1991 Jun;20(2):480–489. doi: 10.1093/ije/20.2.480. [DOI] [PubMed] [Google Scholar]
  65. Steimer K. S., Scandella C. J., Skiles P. V., Haigwood N. L. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science. 1991 Oct 4;254(5028):105–108. doi: 10.1126/science.1718036. [DOI] [PubMed] [Google Scholar]
  66. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol. 1995 Jul;69(7):4413–4422. doi: 10.1128/jvi.69.7.4413-4422.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Sun N. C., Ho D. D., Sun C. R., Liou R. S., Gordon W., Fung M. S., Li X. L., Ting R. C., Lee T. H., Chang N. T. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol. 1989 Sep;63(9):3579–3585. doi: 10.1128/jvi.63.9.3579-3585.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Thali M., Moore J. P., Furman C., Charles M., Ho D. D., Robinson J., Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol. 1993 Jul;67(7):3978–3988. doi: 10.1128/jvi.67.7.3978-3988.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Thali M., Olshevsky U., Furman C., Gabuzda D., Posner M., Sodroski J. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol. 1991 Nov;65(11):6188–6193. doi: 10.1128/jvi.65.11.6188-6193.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Torres J. V., Malley A., Banapour B., Anderson D. E., Axthelm M. K., Gardner M. B., Benjamini E. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation. AIDS Res Hum Retroviruses. 1993 May;9(5):423–430. doi: 10.1089/aid.1993.9.423. [DOI] [PubMed] [Google Scholar]
  71. Traincard F., Rey-Cuillé M. A., Huon I., Dartevelle S., Mazié J. C., Benichou S. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins. AIDS Res Hum Retroviruses. 1994 Dec;10(12):1659–1667. doi: 10.1089/aid.1994.10.1659. [DOI] [PubMed] [Google Scholar]
  72. Warrier S. V., Pinter A., Honnen W. J., Girard M., Muchmore E., Tilley S. A. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J Virol. 1994 Jul;68(7):4636–4642. doi: 10.1128/jvi.68.7.4636-4642.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Weiss R. A., Clapham P. R., Weber J. N., Whitby D., Tedder R. S., O'Connor T., Chamaret S., Montagnier L. HIV-2 antisera cross-neutralize HIV-1. AIDS. 1988 Apr;2(2):95–100. doi: 10.1097/00002030-198804000-00004. [DOI] [PubMed] [Google Scholar]
  74. Wu Z., Kayman S. C., Honnen W., Revesz K., Chen H., Vijh-Warrier S., Tilley S. A., McKeating J., Shotton C., Pinter A. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol. 1995 Apr;69(4):2271–2278. doi: 10.1128/jvi.69.4.2271-2278.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Zwart G., Langedijk H., van der Hoek L., de Jong J. J., Wolfs T. F., Ramautarsing C., Bakker M., de Ronde A., Goudsmit J. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology. 1991 Apr;181(2):481–489. doi: 10.1016/0042-6822(91)90880-k. [DOI] [PubMed] [Google Scholar]
  76. de Wolf F., Meloen R. H., Bakker M., Barin F., Goudsmit J. Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2. J Gen Virol. 1991 Jun;72(Pt 6):1261–1267. doi: 10.1099/0022-1317-72-6-1261. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES